|
- Elise A. Olsen,
M.D.
Female pattern hair loss presents as decreased hair density primarily on
the top of the scalp. It has long been hearkened as the female counterpart of
male pattern hair loss, hence the alternative terms male pattern alopecia,
female baldness or androgenetic alopecia. Both men and women with pattern hair
loss have less actively growing hairs and a progressive fineness and shorter
growth of hair in affected areas but the hair loss in women never goes to the
extreme baldness seen in men. Moreover, although male pattern hair loss has
been conclusively shown to be related to the metabolism and binding of male
hormones (androgens) to their target site in the hair follicle, it is not so
clear cut in women. The majority of women with female pattern hair loss do not
have increased levels of male hormones nor other signs of increased androgen
effect and do not respond to anti-androgens with dramatic hair regrowth.
Instead, only women with female pattern hair loss who also have hirsutism (ie
hair growth in male areas such as the beard and/or moustache) or severe acne
and/or irregular menses, typically have documented elevation of serum
androgens. Unlike men with male pattern baldness, women may first present with
female pattern hair loss in the 40 to 50 year old age range as well as in the
teens and 20's, like affected males. Therefore, because of these different
presentations of female pattern hair loss, it has recently been suggested that
it should be classified as "early onset with and without androgen excess" and
"late/postmenopausal onset with and without androgen excess". This new
classification schema for female pattern hair loss will allow researchers to
better evaluate potential causative factors and treatments in each group.
Unlike men with male pattern baldness in which the diagnosis seems
self-evident, women experiencing hair loss should be evaluated by a physician
to determine the cause. It is important that the distribution of the hair loss,
presence or absence of increased shedding and condition of the underlying scalp
be noted. This will help to eliminate the possible confusion with other types
of hair loss including alopecia areata, telogen effluvium or a cicatricial
(destructive) type of hair loss. Typically, blood work is also done at an
evaluation including thyroid function tests, complete blood count and serum
iron stores to screen for other conditions that may cause generalized hair
loss. In the case of a woman with irregular menses and hirsutism, male hormones
(testosterone, DHEAS) and prolactin may be drawn. A scalp biopsy may be very
important to perform to discriminate between these various hair loss conditions
if the diagnosis is in question: it is important that a pathologist familiar
with hair disorders interprets the biopsy.
Once the diagnosis of female pattern hair loss is established, and the patient
assigned to classification as having androgen excess or not, then treatment can
be discussed rationally. Most women with female pattern hair loss will benefit
from topical minoxidil (Rogaine). Topical minoxidil comes in two strengths, 2%
and 5%, with only the 2% currently approved for women with this condition.
Minoxidil encourages hair to move from the resting to actively growing stage
and to grow longer and more vigorously. Some women may show visible regrowth
while others note primarily a stabilization of loss. Side effects of topical
minoxidil are primarily limited to irritation in £ 8% of patients and some
"peach fuzz" growth on the sides of the face in approximately 5%: these are
both readily reversible on stopping the drug.
Finasteride (Propecia) is a drug that inhibits the conversion of testosterone
to dihydrotestosterone, the male hormone deemed most important in causing male
pattern baldness. It has been shown to be highly effective in men with male
pattern baldness and had long been assumed that Propecia would show similar
efficacy in women. Since there can be genital abnormalities in male fetuses of
mothers taking finasteride during pregnancy, only postmenopausal women with
female pattern hair loss were initially studied. Surprisingly, finasteride was
no better than placebo in effecting hair regrowth in these women. Finasteride
and oral anti-androgens have been used to treat hirsutism and in this context,
there have been reports of improvement in those women with concomitant female
pattern hair loss. Large scale studies of younger women with female pattern
hair loss who have excess androgens treated with eiher finasteride or oral
anti-androgens are necessary to definitively decide their effectiveness in this
condition.
-
Olsen EA. Female pattern hair loss. J Am Acad Dermatol 45:S70-80, 2001.
on
female pattern hair loss. The information provided is not
meant to be a substitute for the information obtained at an
evaluation and by discussion with a physician but merely to
encourage understanding of this condition. No questions regarding
individual scenarios will be answered by the NAHRS. No changes
in treatment should be undertaken by a patient without discussion
first with the patient's physician.
-
5% Rogaine has been studied in multicenter trials of women with female pattern
hair loss and has been found to be safe and superior to placebo. However, the
trials did not show statistically superior efficacy to 2% topical minoxidil in
all endpoints tested so it is currently not FDA approved for this indication.
Women and children with alopecia areata have also used 5% Rogaine off label and
again safety has been maintained.
-
There is a gradual change in your blood hormones long before menopause (or its
cousin adrenopause) raises its head. Whether this subtle decrease in
estrogen/progesterone, which often lead to minor changes in the frequency,
amount of flow or duration of menses, actually cause the hair loss needs to be
further studied. This is certainly a common time of life for late onset female
pattern hair loss to appear. You should see your primary care physician or
dermatologist however, for an evaluation to get a definitive diagnosis and to
rule out such medical problems as a thyroid disorder.
-
Product X, and many other products sold as hair cosmetics and not drugs, may
make loose claims to effectiveness. They have not been held to the same
standards as drugs either in providing documentation of effectiveness nor
standardization of manufacture. If they did make the claim to reverse hair loss
or actually effect hair growth, they must go through the FDA's rigorous testing
for drugs, a path many such companies prefer not to do. Most of these products
do little harm, have little positive effect, and are costly.
-
Unless you are deficient in certain vitamins, taking a supplement is unlikely
to change things. Zinc and/or biotin deficiency can cause hair loss but this
usually is in childhood when a genetic problem in the absorption or use of
these vitamins is first unmasked. There is no evidence that people can be
deficient in ginko biloba or echinacea and because of similar unknown negative
effects, these are probably best not taken.
-
We do not know enough about the relationship of human hair growth/loss in women
to estrogens/progestins to warrant making treatment recommendations. Hormone
replacement therapy is unlikely to reverse the hair loss and a decision on its
use should be determined by other factors.
-
Propecia does not work in postmenopausal women with female pattern hair loss.
It has not been tested in premenopausal women with female pattern hair loss
|
|